儿童重症哮喘负担的理解与减轻进展
儿童重症哮喘仅占儿童哮喘的一小部分,在纠正依从性、共病及不良暴露等可干预因素后,高剂量药物仍控制不佳者构成异质性重症哮喘表型。过去十年对儿童难治性重症哮喘病理生理认识显著进步,但急性发作、住院和死亡率仍高,需改变自然史、预防重症发作和肺功能下降的策略。靶向2型炎症的生物制剂管线有望减轻负担,但需对每个患儿详细评估和分型以实施最有效管理。
要点
- 儿童重症哮喘罕见,需先纠正依从性、共病和不良暴露等可干预因素。
- 高剂量药物仍控制不佳者构成异质性重症哮喘表型。
- 靶向2型炎症的生物制剂管线有望减轻负担,但需个体化评估分型。
核心结论
- 儿童重症哮喘占儿童哮喘比例小,但急性发作和住院频繁且死亡率仍不可接受地高。
- 机制研究推动靶向2型炎症生物制剂发展,有望减轻重症哮喘负担。
- 需对每个看似重症哮喘的儿童详细评估和分型以实施最有效管理。
研究设计与样本
- PubMed来源的Lancet Respir Med综述,未报告系统检索范围与样本量。
主要发现
- 儿童重症哮喘在纠正可干预因素后仍高剂量药物控制不佳者构成异质性表型。
- 过去十年对儿童难治性重症哮喘病理生理认识显著进步。
- 哮喘急性发作和住院频繁,死亡率仍不可接受地高。
- 机制研究促成多种靶向2型炎症的生物制剂开发。
临床怎么用
- 对每个看似重症哮喘的儿童进行详细评估和分型以选择最有效管理策略。
- 风险分层、远程监测和多数据源整合可帮助个体化 tailoring 管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe asthma in children is rare, accounting for only a small proportion of childhood asthma. After addressing modifiable factors such as adherence to treatment, comorbidities, and adverse exposures, children whose disease is not well controlled on high doses of medication form a heterogeneous group of severe asthma phenotypes. Over the past decade, considerable advances have been made in understanding the pathophysiology of severe therapy-resistant asthma in children. However, asthma attacks and hospital admissions are frequent and mortality is still unacceptably high. Strategies to modify the natural history of asthma, prevent severe exacerbations, and prevent lung function decline are needed. Mechanistic studies have led to the development of several biologics targeting type 2 inflammation. This growing pipeline has the potential to reduce the burden of severe asthma; however, detailed assessment and characterisation of each child with seemingly severe asthma is necessary so that the most effective and appropriate management strategy can be implemented. Risk stratification, remote monitoring, and the integration of multiple data sources could help to tailor management for the individual child with severe asthma.
引用
- Pijnenburg MW, Fleming L. Advances in understanding and reducing the burden of severe asthma in children. Lancet Respir Med. 2020. PMID: 32910897. doi:10.1016/S2213-2600(20)30399-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。